APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development

"We are excited to announce our collaboration with Biogen. It has been a fruitful collaboration to combine expertise from both companies to advance our understanding of 18F-APN-1607 and to discover next generation imaging tracers," said Ming-Kuei Jang, CEO of APRINOIA. "APRINOIA is committed to make 18F-APN-1607 and our other imaging tools available to research and medical communities to explore clinical utilities of those tools and facilitate clinical research of potential treatments for neurodegenerative diseases."

"We are excited to announce our collaboration with Biogen. It has been a fruitful collaboration to combine expertise from both companies to advance our understanding of ¹⁸F-APN-1607 and to discover next generation imaging tracers," said Ming-Kuei Jang, CEO of APRINOIA. "APRINOIA is committed to make ¹⁸F-APN-1607 and our other imaging tools available to research and medical communities to explore clinical utilities of those tools and facilitate clinical research of potential treatments for neurodegenerative diseases."

About APRINOIA

APRINOIA Therapeutics is currently advancing a pipeline featuring diagnostic and therapeutic programs, collectively targeting brain disorders associated with abnormal accumulation of pathological proteins, including tau and alpha-synuclein, from its proprietary small molecule and antibody discovery platforms. APRINOIA is committed to building a pipeline of innovative products, as well as developing partnership with global and regional pharmaceutical companies to accelerate its programs. The company currently has operations in Taipei, Suzhou, Shanghai, Tokyo, and Boston.

Contact: Ms. Mingwei Pu, Email: [email protected]